Background/Aims: Aortic dissection (AD) is also known as intramural hematoma. This study aimed to screen peripheral blood biomarkers of small molecule metabolites for AD using high-performance liquid chromatography-mass spectrometry (HPLC-MS). Methods: Sera from 25 healthy subjects, 25 patients with well-established AD, and 25 patients with well-established hypertension were investigated by HPLC-MS to detect metabolites, screen differentially expressed metabolites, and analyze metabolic pathways. Results: Twenty-six and four metabolites were significantly up-and down-regulated in the hypertensive patients compared with the healthy subjects; 165 metabolites were significantly up-regulated and 109 significantly down-regulated in the AD patients compared with the hypertensive patients. Of these metabolites, 35 were up-regulated and 105 down-regulated only in AD patients. The metabolites that were differentially expressed in AD are mainly involved in tryptophan, histidine, glycerophospholipid, ether lipid, and choline metabolic pathways. As AD alters the peripheral blood metabolome, analysis of peripheral blood metabolites can be used in auxiliary diagnosis of AD. Conclusion: Eight metabolites are potential biomarkers for AD, 3 of which were differentially expressed and can be used for auxiliary diagnosis of AD and evaluation of treatment effectiveness.
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Cellular Physiology and Biochemistry use, a history of venous thrombosis or myocardial infarction, and the presence of severe liver and kidney dysfunction or serious electrolyte disorders. Among the AD patients, only two were free from hypertension or inherited hypertension (HP). Clinical data for the AD group are summarized in Table 1 . HP patients (contractive pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg before hypertension treatment) were randomly selected from May 30 to November 23, 2016 , including those with a confirmed diagnosis of hypertension in our hospital or hypertensive patients without other cardiovascular diseases according to a physical examination. Clinical data for the HP group are summarized in Table 2 .
A normal control (NC) group was selected from May 30 to September 5, 2016 , comprising normal adults without cardiovascular diseases or family genetic diseases. Their blood fat, blood glucose, blood pressure, and hepatonephric function indices were all within normal ranges.
This study was approved by the Ethics Committee of Renmin Hospital, and informed consent was obtained from each participant.
Sample collection
All whole-blood samples were collected at the hospital on the morning after confirmed diagnosis. Intravenous blood collection tubes were used to collect 1.5 mL of whole blood from each participant; the immediate clinical laboratory test required approximately 0.5 mL, and the remaining 1.0 mL was used for serum separation. Each whole blood sample was incubated at 37 °C for 1-2 h and centrifuged at 2000 r/min for 5 min; the supernatant, considered the serum, was immediately frozen at -80 °C. 
Mass spectrometry analysis parameters and conditions
The chromatographic conditions were as follows. An Agilent QTOF-6545 system with a microfluidic high-performance liquid phase was used with Eclipse-C18 columns (3×100 mm, 1. 8 μm). The column temperature was 40 °C. Mobile phase A was water (V/V) (containing 0.1% formic acid), and mobile phase B was acetonitrile (containing 0.1% formic acid). The flow rate was 0.3 mL/min, and the injection volume was 4 μL; the mobile-phase gradients are shown in Table 3 Table 3 .
Instrument stability test
A total of 2 μL of each sample was mixed well and centrifuged, and 4 μL of the supernatant was successively injected 6 times. Under the exact same test conditions, the stability of the instrument was examined according to the overlap of the original chromatograms. The stability of the database was evaluated, and analysis was performed according to the different types of metabolites obtained from the 6 injections. The final results were organized into a two-dimensional data matrix in EXCEL 2007, including variables (rt-mz, i.e., the retention time-mass-to-charge ratio), observed quantity (sample), and peak intensity (normalization processing), and the data were entered into SIMCA-P (13.0) for multivariate statistical analysis, as shown in Fig. 1 . The mass spectrometry results were analyzed using MPP software to identify metabolites, and metabolites with significant differences were analyzed using Kyoto Encyclopedia of Genes and Genomes (KEGG) for signaling pathway analysis.
S t a t i s t i c a l analysis

Results
General data
General data obtained for the three groups are summarized in Table 4 . No significant differences were found with regard to gender ratio or mean age.
Instrument calibration and differential analysis of samples in the same group
The Agilent QTOF-6545 instrument was calibrated prior to testing, and stability was examined on the testing day. The results are shown in Fig. 2 . The HPLC chromatograms of all six injections overlapped, without any separation, indicating that the instrument was functioning properly with excellent stability. A total of 1426 metabolites were assessed in the 6 tests, and good relative standard deviation (RSD) values were obtained for 1302.
Ten samples were then randomly selected from each of the three groups, and cluster analysis was performed on the data. As shown in Fig. 3 , the consistency of the samples was significantly higher in the AD group than in the other groups, though the correlation of the AD group with the other groups was low. This finding shows that the grouping was very good, and the low correlation between groups indicated that searching for biomarkers based on this test was feasible.
Statistical analysis of samples and distributions of different metabolites
The data arrays were normalized for more intuitive and reliable results before they were formally analyzed using SMICA-P13.0 software. The principle component analysis (PCA) modeling approach was applied to evaluate differences between two groups, and the results are shown in Fig. 4 .
PCA analysis of the three groups showed that the groupings were very good, the associations within the groups were very high, and the differences between groups were large. A strong correlation was found between the NC and HP groups, and a large difference was found between the main components in the AD group and the NC and HP groups. PC1 separated the NC and HP groups from the AD group, indicating that the metabolomes of the NC and HP patients were significantly different from those of the AD patients. PC2 separated the HP group from the NC group, indicating that the metabolomes of the former patients were different from those of the latter. The difference between the NC and AD groups or between the HP and AD groups was larger than the difference between the NC and HP groups.
As presented in Fig. 4B , the corresponding differentially expressed metabolites among the components of the three groups were obtained by PCA characteristic analysis, and the related metabolites were analyzed by database comparison. To validate the differentially expressed metabolites in the three groups, components were analyzed using a volcano plot (Fig. 4C) .
As shown in Table 5 , 236 differentially expressed metabolites were found in the AD patients compared to the healthy subjects by HPLC-MS analysis, of which 142 were significantly up-regulated and 64 significantly down-regulated. A total of 165 different metabolites were found in the AD patients compared with the patients with hypertension, of which 109 were significantly down-regulated and 56 significantly up-regulated. There were 26 differ- Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry entially expressed metabolites in the hypertensive patients compared with the healthy subjects, of which four were down-and 21 up-regulated. Compared with the NC group, both the AD and HP groups exhibited differential expression of N,N-dimethyl-safingol, aminopentol, sphinganine, phytosphingosine, bacteriochlorophyllide a, proline betaine, nipecotic acid, phosphinothricin, and Gly Ala Lys (all P<0.05). Eight metabolites in the peripheral blood of the AD group were strongly different compared to the NC and hypertension groups (Table  6 ); these metabolites were also highly expressed in the peripheral blood of the AD group in comparison with the other components. Among them, three [N1-acetyl-N2-formyl-5-methoxykynuramine (AFMK), glycerophosphocholine, and 2-mercapto histidine betaine (ergothioneine)] showed maximum differences, with peripheral blood levels more than 50 times higher in the AD patients compared with normal human subjects. To further validate the obtained outcomes, the presence of the three substances in each patient of the AD and HP groups relative to the NC group was compared, and the results are summarized in Table 7 .
The levels of AFMK in the AD group were all significantly higher than those in the HP group, and more than 85% of the AD patients had significantly higher glycerophosphocholine levels compared to the HP group. Approximately 60% of the AD patients had significantly higher levels of ergothioneine compared to the HP group, and the remaining 40% of AD patients had higher or at least not lower levels than the latter. The chemical formulas for AFMK, glycerophosphocholine, and ergothioneine are shown in Fig. 5 . These results suggest that the combined use of the three biomarkers has high accuracy for AD screening and diagnosis from peripheral blood. Additionally, more than 50 novel substances were identified in the peripheral blood of the AD group, of which two (tetranor-PGE1 and 13, 14-dihydro-19 (R)-hydroxyPGE1) may serve as potential metabolite biomarkers for AD in peripheral blood. These findings will help reveal the pathogenesis of AD.
Potential signaling pathways
Analysis of the metabolic pathways of the three metabolites with maximally differential expression (AFMK, glycerophosphocholine, and ergothioneine) showed that they are mainly involved in the tryptophan, histidine, glycerophospholipid, ether lipid, and choline metabolic pathways (http://www.kegg.jp/ kegg-bin/search_pathway_text?map=map&keyword=C00670&mode=1&viewImage=true; http://www.kegg.jp/kegg-bin/search_pathway_text?map=map&keyword=C05642&mode= 1&viewImage=true; http://www.kegg.jp/kegg-bin/search_pathway_text?map=map&keyw ord=C05570&mode=1&viewImage=true). 
Discussion
AD is a serious disease that is generally complicated by hypertension. However, the pathogenesis of AD is unclear at present, and the changes in whole-body metabolism that are associated with the disease have rarely been reported. AD has an acute onset and is a serious condition; the early mortality of untreated AD is approximately 1%-2% per hour [5] . Moreover, the rate of missed diagnosis for AD in the emergency department is as high as 50%, and only 25% of patients with AD are clearly diagnosed by autopsy after death [5, 9] . Indeed, this delayed diagnosis has become an important factor leading to increased risk of AD-associated morbidity and mortality [7] . For patients with clinical chest and back pain who are suspected of having AD, there is an urgent need to establish a set of highly sensitive and specific clinical indicators for the early diagnosis of AD in the clinic.
With the recent rapid development of molecular biological technology and the universal application of various new instruments, screening of disease markers, such as protein macromolecules and small-molecule metabolites, is highly desirable. There has been significant progress made in the application of all types of biomarkers for the diagnosis and treatment of diseases, which is useful to clinicians, and molecules such as smMHC, CK-BB, and MMPs [14, 15] have been used in some clinical testing applications. However, there are issues with the application of these biomarkers, inhibiting their widespread implementation for clinical detection. Although smMHC has good sensitivity for early detection of AD, the effective time window is short. Similarly, sFLAF cannot be detected in AD patients with thrombosis within false lumens, even though this molecule is continuously elevated for 72 h. A growing number of studies have found that combined detection of a variety of candidate biomarkers may greatly contribute to the diagnosis of AD, and many peripheral serum markers for AD patients with prognostic significance, such as D-dimer and serum endothelin [16] , have undergone in-depth research. AD  HP  AD  1  15  150  44  223  22  27  2  22  173  53  189  17  35  3  3  167  67  210  28  19  4  2  200  55  201  20  38  5  38  201  58  89  33  17  6  31  401  60  279  18  98  7  59  98  No detection  333  40  82  8  12  339  71  398  19  33  9  0.9  201  20  168  22  109  10  No detection 221  21  281  39  90  11  30  187  49  199  11  16  12  11  160  71  72  31  189  13  9  429  79  331  18  176  14  3  94  42  381  22  153  15  20  113  No detection  210  27  132  16  38  82  66  440  26  40  17  35  90  38  342  16  104  18  4  118  77  264  9  15  19  17  99  62  282  12  113  20  10  93  66  77  19  99  21  No detection  85  61  89  33  148  22  39  389  30  381  10  112  23  22  88  41  288  4  88  24  13  97  44  482  7  69  25  44  133  43  231  24  93  26  31  203  62  292  21  118  27  60  210  66  365  30  69  28  16  115  No detection  382  27  26  29  26  332  80  401  16  17  30  0.8  279  71  392  4  29 Cellular Physiology and Biochemistry
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In previous studies, the use of peripheral blood biomarkers to diagnose AD showed strong clinical feasibility. For example, these biomarkers can be used for initial screening for AD, and when related indices are abnormal, imaging can be performed for AD confirmation. Such biomarkers can also be used for treatment efficiency follow-up. Additionally, these biomarkers can be used to initially predict patient prognosis. However, previous studies have focused on peripheral blood markers, such as growth factors, enzymes, inflammatory responses, proteins, peptide chain precursors, and other macromolecular proteins [12] [13] [14] [15] . Although such studies offer effective information for the early diagnosis and prognosis of AD and also provide constructive suggestions for AD pathogenesis elucidation, due to the intrinsic particularity of protein macromolecules, their dissemination in clinical detection for AD faces many challenges, including determining the preservation and testing conditions, diagnosis interval, and cost. Peripheral blood metabolic biomarkers have gained more attention with the development of HPLC-MS technology, our increasing understanding of the metabolic pathways of small molecules, and the gradual perfection of small molecule databases [20] [21] [22] . In the present study, metabolites in the peripheral sera of patients with AD were examined by HPLC-MS and compared with corresponding metabolite levels in healthy subjects and hypertensive patients. Eight metabolites were significantly up-regulated in the peripheral sera of AD patients, among which three may be used as potential peripheral blood biomarkers for AD.
A total of 236 differentially expressed metabolites were found in AD patients compared with healthy subjects, of which 142 were significantly up-regulated and 64 significantly down-regulated. In addition, 165 differentially expressed metabolites were found in AD patients compared with patients with hypertension, of which 109 were significantly downand 56 up-regulated. Compared with healthy subjects, 26 differentially expressed metabolites were found in hypertensive patients, with four being down-regulated and 21 up-regulated. Eight metabolites in the peripheral sera of the AD group were differentially expressed compared to the NC and hypertension groups; these metabolites were also highly expressed in the peripheral sera of the AD group compared with other components. Among them, three metabolites (AFMK, glycerophosphocholine, and ergothioneine) exhibited maximum differences, with levels in AD patient peripheral sera that were more than 50 times higher than in normal human peripheral sera. The combination of these differentially expressed biomarkers may be used for the identification and diagnosis of AD as well as differential diagnosis between AD and hypertension. Furthermore, more than 50 novel substances were identified in the peripheral sera of the AD group, two of which (tetranor-PGE1 and 13, 14-dihydro-19 (R)-hydroxyPGE1) may serve as potential serum metabolite biomarkers for AD. This finding will contribute to further exploration of AD pathogenesis. Additionally, an increased level of one natural product (sphingofungin B) was found in the AD patient samples compared to the other components, and the presence of a natural product in patient sera is an interesting finding. According to our analysis of the metabolic pathways of the three metabolites with maximally differential expression (AFMK, glycerophosphocholine, and ergothioneine), these differentially expressed metabolites are mainly involved in metabolic pathways underlying tryptophan, histidine, glycerophospholipid, ether lipid, and choline metabolism [23] .
This study has some limitations. First, in accordance with the requirement that a biomarker for AD should be easy to manipulate and have rapid detection, we set the cut-off values at 50-fold when identifying differently expressed metabolites between the AD and HP groups. However, it remains to be explored whether other differently expressed metabolites can be used as effective biomarkers for AD. Second, due to our limited research capacities and research funding, we did not analyze and compare associations between well-reported protein markers for AD (such as smMHC, CK-BB, D-dimer, MMPs, and elastin) and the metabolite markers found in this study. Determining whether these metabolite markers are the downstream products of protein markers or whether their accumulation may influence protein expression is the focus of our future research. Additionally, although we found differences between metabolites and pathways in peripheral sera of AD patients, NCs, and hypertensive patients, we did not determine the specific cellular sources of these metabolic substances or differences in their corresponding enzymes and upstream gene levels [24] . An important goal of our next study is to specify the association and differences between these peripheral blood markers and existing protein markers for AD.
Conclusion
In summary, application of an established detection method to assess changes in peripheral blood AFMK, glycerophosphocholine, and ergothioneine levels in AD patients by HPLC-MS for early diagnosis of AD has good specificity and sensitivity. This method will contribute to the screening and early diagnosis of AD and can be used to complement the current diagnosis of aortic diseases.
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